Stock Price Quote

LAURUS LABS LTD.

NSE : LAURUSLABSBSE : 540222ISIN CODE : INE947Q01028Industry : Pharmaceuticals & DrugsHouse : Private
BSE432.75-1.65 (-0.38 %)
PREV CLOSE ( ) 434.40
OPEN PRICE ( ) 432.25
BID PRICE (QTY) 432.35 (8)
OFFER PRICE (QTY) 432.70 (8)
VOLUME 15641
TODAY'S LOW / HIGH ( )431.40 437.50
52 WK LOW / HIGH ( )279.65 470.9
NSE432.65-1.75 (-0.4 %)
PREV CLOSE( ) 434.40
OPEN PRICE ( ) 434.45
BID PRICE (QTY) 432.50 (165)
OFFER PRICE (QTY) 432.90 (186)
VOLUME 317946
TODAY'S LOW / HIGH( ) 431.80 437.90
52 WK LOW / HIGH ( )278.85 471
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 19-09 2005
Management Info
Malempati Venugopala Rao - Chairman - Managing Director
Registered Office

Address Laurus Enclave, Plot Office 01,Edulapakabonangi Village, Parawada,Mandal, Anakapalli,
Vishakhapatnam,
Andhra Pradesh-531021

Phone 0891 3061222 / 6601222

Email info@lauruslabs.com

Website www.lauruslabs.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

19Apr USFDA completes inspection at Laurus L
United States Food & Drug Administration (USFDA) has completed inspe..
30Mar Laurus Labs informs about closure of t
Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015,..
19Feb Laurus Labs invests over Rs 99 crore i
Laurus Labs has infused further equity into its wholly-owned subsidiary..
19Feb Laurus Labs soars on investing over Rs
Laurus Labs is currently trading at Rs. 409.05, up by 9.40 points or 2.3..
17Feb Laurus Labs informs about updates on a
With reference to disclosures dated May 31, 2023 and July 12, 2023 regar..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit426.47603.8
Gross Profit 567 10514.3
Operating Profit 181114977.1
Net Sales 11321.957734.5

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

NGL Fine-Chem (BSE)
peergroup  2736.60 (4.41%)
M.Cap ( in Cr)1619.26
Vimta Labs (BSE)
peergroup  575.00 (12.87%)
M.Cap ( in Cr)1129.48
Bharat Parenterals (BSE)
peergroup  1600.00 (3.42%)
M.Cap ( in Cr)900.36
Astrazeneca Pharma I (BSE)
peergroup  5304.10 (0.66%)
M.Cap ( in Cr)13173.25
JB Chem & Pharma (BSE)
peergroup  1851.00 (1.46%)
M.Cap ( in Cr)28314.52

Shareholding Pattern

MUTUAL FUNDS/UTI 6.68%
FI/BANKS/INSURANCE 4.75%
NON-INSTITUTION 35.07%
PROMOTERS 27.19%
GOVERNMENT 0%
FII 0%

About Laurus Labs Ltd.

Laurus Labs Ltd. was incorporated in the year 2005. Its today's share price is 432.75. Its current market capitalisation stands at Rs 23412.68 Cr. In the latest quarter, company has reported Gross Sales of Rs. 57734.5 Cr and Total Income of Rs.57894 Cr. The company's management includes G Venkateswar Reddy, Lakshmana Rao CV, Venkata Ravi Kumar Vantaram, Ravindranath Kancherla, Rajesh Koshy Chandy, Aruna Bhinge, Satyanarayana Chava, Malempati Venugopala Rao.

It is listed on the BSE with a BSE Code of 540222 , NSE with an NSE Symbol of LAURUSLABS and ISIN of INE947Q01028. It's Registered office is at Laurus Enclave, Plot Office 01,Edulapakabonangi Village, Parawada,Mandal, AnakapalliVishakhapatnam-531021, Andhra Pradesh. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP, SR Batliboi & Associates LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.